RIGL · Biopharmaceuticals (Small-cap)
Rigel Pharmaceuticals, Inc.
SpeculativeThe business
Rigel Pharmaceuticals is a small-cap biopharmaceutical company commercialising approved therapies in hematology and oncology while advancing a pipeline behind them. The thesis is less flywheel than special situation: a company transitioning from clinical risk toward a base of recurring, cash-generative product revenue.
The flywheel
Approved products generate revenue that funds the pipeline; pipeline wins broaden the commercial base and the sales infrastructure that carries the next launch. The loop is narrower and more binary than our platform holdings — progress depends on clinical and commercial milestones rather than self-reinforcing scale.
Why we own it
- A path from clinical-stage risk toward recurring product revenue.
- Commercial infrastructure that can carry additional launches.
- Asymmetric upside if pipeline and partnerships deliver.
- Small sizing makes it a contained, optionable position.
Key risks
- Binary clinical, regulatory, and reimbursement outcomes.
- Small-cap volatility and potential financing needs.
- Competition and limited diversification across products.
Our recommendation
A speculative special situation held in small size. We underwrite it as an asymmetric option on commercial execution, not as a compounding core holding, and we watch the milestones closely.
This note reflects the views of Flywyl as of May 2026 and is provided for informational purposes only. It is not investment advice, an offer, or a solicitation to buy or sell any security. Views and positioning may change without notice. Past performance does not guarantee future results, and all investments carry risk of loss. Figures and qualitative ratings are illustrative of our internal framework and should be independently verified.